|Bid||53.85 x 3100|
|Ask||53.87 x 3100|
|Day's Range||53.54 - 54.05|
|52 Week Range||46.48 - 64.94|
|Beta (5Y Monthly)||0.21|
|PE Ratio (TTM)||35.51|
|Forward Dividend & Yield||1.40 (2.60%)|
|Ex-Dividend Date||Feb 25, 2021|
|1y Target Est||63.60|
The European Union cemented its support for Pfizer-BioNTech and its novel COVID-19 vaccine technology Saturday by agreeing to a massive contract extension for a potential 1.8 billion doses through 2023.
In this article, we will take a look at the 10 best UK stocks to buy now. You can skip our comprehensive analysis of these British companies and go directly to the 5 Best UK Stocks to Buy Now. The COVID-19 pandemic hit the United Kingdom as hard as the rest of the world, resulting […]
AstraZeneca (NASDAQ: AZN) and its partner Sanofi (NASDAQ: SNY) recently announced promising results from a late-stage study of nirsevimab in preventing respiratory syncytial virus (RSV) in infants. In this Motley Fool Live video recorded on April 28, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the two companies can win big with this experimental RSV therapy.